Increasing prevalence of chronic and genetic diseases is expected to drive the growth of global cloning & mutagenesis in the forecast period, 2024-2028.
According to TechSci Research report, “Cloning & Mutagenesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F”, the global cloning & mutagenesis market is anticipated to grow at an impressive rate in the forecast period, 2024-2028. This can be ascribed to the increasing prevalence of chronic and genetic diseases like cancer and HIV, along with growing healthcare expenditure across the globe. Additionally, growing investment on research and development for the treatment of genetic disorders and other diseases, especially in the developed countries in the North America and Europe, is expected to create lucrative opportunities for the market growth in the coming years. Besides, increasing demand for laboratory automation and more awareness of preventive healthcare is further expected to support the market growth. Similarly, the increasing demand for personalized medicine adoption of cloning and mutagenesis tools have increased such as PCR is expected to boost the market growth during the forecasted period. Also, the growing focuses on protein engineering for drug development is expected to drive the growth of the market. Additionally, growing demand for genetically modified products such as crops is anticipated to drive the growth of the market over the years.
However, high cost of cloning and mutagenesis kits can create affordability issues thereby slowing down the growth of global cloning & mutagenesis market in the forecast period. Similarly, high risks and complications associated with treatments, may hamper the cloning & mutagenesis market growth during the forecast period. Also, lack of accuracy in methods of cloning and mutagenesis, along with ethical issues surrounding the terminology in emerging countries, can further restrict the growth of global cloning & mutagenesis market. Also, lack of infrastructure and instruments may hamper the growth of the market during the forecasted years.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Cloning & Mutagenesis Market"
The global cloning & mutagenesis market can be segmented by gene type, by product type, by technique, by application, by end user and by region.
Based on product type, the global cloning & mutagenesis market can be divided into Cloning Kits v/s Mutagenesis Kits. The Mutagenesis Kit segment dominated the market in 2022 and is expected to continue maintaining its dominance throughout the forecast period. This can be ascribed to increasing demand for early detection of chronic diseases such as cancer and HIV for better treatment and diagnosis across the region and helping immunocompromised patients. Also, growing applications of mutagenesis kits in biomedical research and adoption of this advanced kits in research and development can boost the market growth during the forecasted years.
Based on Application, the market can be segmented into Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, Others. The Vaccine Research segment is expected to dominate during the forecast period on account of increasing demand for personalized medicine for the treatment of chronic diseases like HIV and Cancer.
Major companies operating in global cloning & mutagenesis market are:
- Agilent Technologies, Inc.
- Eurofins Scientific SE
- Sartorius AG
- Collecta, Inc.
- Codex DNA Inc.
- Lonza Group AG
- Charles River Laboratories International, Inc.
- TransGene Biotech Co. Ltd.
- Takara Bio, Inc.
- Thermo Fisher Scientific Inc.
For instance, in November 2021, Genes2Me launched a molecular product range, which includes cloning, next-generation technology, and enzyme technology among other product categories. The product range contains the Fantom High-Fidelity PCR DNA polymerase, which can significantly improve PCR test sensitivity, making it a feasible cornerstone for cloning technology.
For instance, in October 2022, GM mustard was approved by Genetic Engineering Appraisal Committee GEAC for commercial release. This initiative is expected to catalyze crop improvement to meet nutritional needs.
Customers can also request for 10% free customization on this report.
“The North America is expected to dominate in the global cloning & mutagenesis market on account of increasing investment by government organizations for the development of stem cell and cancer research across the region. Furthermore, increasing number of biotechnology companies in the region, along with increasing prevalence of chronic diseases, are further contributing to the demand for cloning and mutagenesis market. Besides, increasing demand for adopting personalized medicine services and developing healthcare systems for the treatment of different type of chronic diseases like breast cancer, prostate cancer, blood cancer in the region, are further expected to create lucrative opportunities for the market growth” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Cloning & Mutagenesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F, Segmented By Gene Type (Standard v/s Complex), By Product Type (Cloning Kits v/s Mutagenesis Kits), By Technique (Topo PCR Cloning, Blunt End Cloning, Seamless Cloning, Site-Directed Mutagenesis, Others), By Application (Gene Synthesis, Gene Expression, Gene Therapy, Vaccine Research, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Others), By Region and Competition”, has evaluated the future growth potential of global cloning & mutagenesis market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global cloning & mutagenesis market.
Mr. Ken Mathews
708 Third Avenue,
New York – 10017
Email: [email protected]m
Showing 1 reaction
Sign in with